GHP November 2017 - Rejuvenation Dentistry

GHP / November 2017 17 IV Antibiotic That Could Reduce Pressure on the NHS g 1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179 http://www.nejm.org/doi/full/10.1056/NEJMoa1310480 2. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single dose vs weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545-551 https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4741365/pdf/civ982.pdf 3. Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Saf. 2016 Feb;39(2):147-57 https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4735234/pdf/40264_2015_Article_374.pdf 4. Real-World Practice Patterns for the Treatment of Complicated Skin and Soft Tissue Infections in Europe: A Retrospective Database Analysis. The Medicines Company, 2015 5. Emergency Admissions for Ambulatory Care Sensitive Conditions – characteristics and trends at national level. NHS England, March 2014 6. Chapman A. Outpatient Parental Antimicrobial Therapy. BMJ (Published 26 March 2013) 7. Data on file (Allergan) 8. UK Five Year Antimicrobial Resistance (AMR) Strategy 2013-2018 https:// www.gov. uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018 (Accessed March 2017) 9. Livermore DM, Mushtaq S, Warner M, James D, Kearns A, Woodford N. Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. J Antimicrob Chemother 2015; 70 (10) 2844-2853. Doi: 10.1093/ jac/dkv179 10. Health & Social Care Information Centre. Hospital Episode Statistics. 11. Government Data https://data.gov.uk/data-request/nhs-hospital-stay (Accessed March 2017) 12. Nuffield Trust analysis of hospitals in England Early and effective treatment of ABSSSI is critical to optimise patient recovery and also help to avoid potentially lengthy and costly hospital stays. In 2013-2014, there were 104,598 recorded cases of cellulitis (a type of ABSSSI) treated in secondary care in the UK. Of these, 69,229 hospital admissions involved a mean and median bed stay of 6.2 and three days, respectively. 10 The average cost of an NHS hospital stay is around £400 per day 11 and bed capacity in hospitals is currently a major issue for the NHS. On average, more than 95% of hospital beds were occupied every day in winter 2016 (the target is a maximum of 85%) and on a single busiest day, 4,390 additional beds were opened to cope with the extra pressure. 12 This article is supported by Cardiome UK Ltd. XYUK19102017PR October 2017 Adverse events should be reported. Reporting forms and information can be found at www. mhra.gov.uk/yellowcard. Adverse events should also be reported to Cardiome UK Ltd (Tel: +44 (0)203 002 8114 ). About ABSSSI ABSSSI are bacterial infections of skin and associated tissues primarily caused by Gram- positive pathogens, including Staphylococcus aureus and Streptococcus pyogenes. While ABSSSI are common, these infections can be serious and may be life-threatening. The majority of all skin and soft tissue infections in hospital outpatients are caused by streptococci and Staphylococcus aureus, and approximately 15.8% of these S. aureus infections in the UK are estimated to be caused by MRSA. 9